ChariotMS – Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

ChariotMS – Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Publication date: Jan 05, 2021

MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide. Without disease modifying treatment (DMT),the majority of people with MS (pwMS) will develop significant disability within 10 years of onset, and 50% will require wheelchair assistance within 20 years. convenient, highly effective and CNS penetrant DMT for patients with relapsing multiple sclerosis (pwRMS) administered in short (8-10 days/year over 2 years) treatment courses. It effectively depletes B cells, particularly Memory B cells, a likely key mechanism of disease control in MS. Cladribine is the investigational product in this study as it not currently used to treat patients with an EDSS of 6.5 – 8.5. This is a multi-centre, randomised double-blind placebo-controlled phase IIb to test cladribine tablets (MAVENCLAD(R)) (3.5mg/kg over 24 months) for safety, efficacy, and cost effectiveness, and to advance mechanistic understanding of its action in people with advanced MS (pwAMS).

Concepts Keywords
Arterial Hypertension McDonald criteria
Bowel Multiple sclerosis
Breast Screening EDSS
Breastfeeding Purines
Cardiac Failure Organochlorides
Central Nervous System Cladribine
Cervical Organ systems
Cladribine Medical specialties
Comorbidity Nervous system
Confirmation Autoimmune diseases
Creatinine Clearance Multiple Sclerosis
Deep Vein G cardiac failure
Diabetes Venous thrombosis
Disability MS
DMT
Double Blind
Hypercholesterolaemia
Hypersensitivity
London
London Drugs
Malignancy
Multiple Sclerosis
Myocardial Infarction
NHS
Nhs
Penetrant
Phase IIb
Placebo
Queen Mary
Renal Failure
Renal Impairment
Sinus
Stroke
Tablets
Venous Thrombosis
Wheelchair

Semantics

Type Source Name
disease MESH renal failure
disease MESH cardiac failure
disease MESH comorbidity
drug DRUGBANK Creatinine
disease MESH myocardial infarction
disease MESH venous thrombosis
drug DRUGBANK Cladribine
disease MESH Multiple Sclerosis
drug DRUGBANK Dimethyltryptamine
disease MESH cancer
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH stroke
disease MESH hypertension
disease MESH hypersensitivity
disease MESH diagnosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *